Home > Healthcare > Pharmaceuticals > Finished Drug Form > Alpha-glucosidase Inhibitors Market

Alpha-glucosidase Inhibitors Market Trends

Report ID: GMI10795
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Alpha-glucosidase Inhibitors Market Trends

The rising prevalence of type 2 diabetes is a significant driver of the market. With the increasing incidence of obesity, sedentary lifestyles, and unhealthy dietary habits, type 2 diabetes has become a global health concern, leading to a growing demand for effective treatments.
For instance, according to the International Diabetes Federation (IDF) Diabetes Atlas, in 2022, approximately 537 million adults aged 20-79 were living with diabetes globally. This figure represents about 10.5% of the adult population in that age group. The IDF predicts that this number will rise to 643 million by 2030 and 783 million by 2045.
The surge in type 2 diabetes cases has heightened the need for diverse and effective antidiabetic medications, positioning alpha-glucosidase inhibitors as a crucial component in the management of this chronic condition.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Alpha-glucosidase inhibitors market size was worth USD 3.3 billion in 2023 and will grow at a 3.2% CAGR between 2024 and 2032, propelled by the rising prevalence of diabetes and obesity, increasing awareness of diabetes management, and the growing elderly population.

Alpha-glucosidase inhibitors industry in the type 2 diabetes mellitus segment captured 86.3% share in 2023 due to the high global prevalence of this condition, particularly in aging and obese populations.

North America alpha-glucosidase inhibitors industry will witness 2.8% CAGR through 2032, owing to the high prevalence of type 2 diabetes, robust healthcare infrastructure, and increasing awareness of diabetes management.

Some of the leading alpha-glucosidase inhibitors industry players include Alkem Laboratories Ltd., Bayer AG, Cipla Limited, Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Lupin Ltd., Merck & Co., Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company, Torrent Pharmaceuticals Ltd., and Unichem Laboratories Ltd., among others.